EZR and neoplasm: In contrast, the 5-year EFS for patients whose tumor showed high ezrin intensity was 78% (95% CI: 57%–93%) compared to 55% (95% CI: 35%−74%) for those with low ezrin intensity (P = 0.03; Figure 2).